HHC
IONS icon

Hutchin Hill Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Hutchin Hill Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-64,800
Closed -$2.6M – 934
2017
Q1 		$2.6M Buy
+64,800
New +$2.91M 0.07% 272

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Hutchin Hill Capital's IONS Position: Q2 2017 in Review

Hutchin Hill Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2017, closing a stake of 64,800 shares — an estimated $2.6M sold.

Hutchin Hill Capital first reported a position in IONS in Q1 2017 and held it in 1 quarter. The position peaked at $2.6M in Q1 2017. 293 funds tracked by Wall St. Rank hold IONS as of Q2 2017.

  • Hutchin Hill Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 64,800 Ionis Pharmaceuticals shares in Q2 2017, an estimated $2.6M.
  • Hutchin Hill Capital first reported a position in Ionis Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Hutchin Hill Capital's Ionis Pharmaceuticals position peaked at $2.6M in Q1 2017.
  • 293 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2017.

Based on Hutchin Hill Capital's 13F filing for Q2 2017, filed 14 Aug 2017.